Quantitative high-resolution CpG island mapping with Pyrosequencing™ reveals disease-specific methylation patterns of the CDKN2B gene in Myelodysplastic syndrome and myeloid leukemia

被引:55
作者
Brakensiek, Kai
Wingen, Luzie U.
Langer, Florian
Kreipe, Hans
Lehmann, Ulrich
机构
[1] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany
[2] John Innes Ctr, Dept Dis & Stress Biol, Norwich, Norfolk, England
关键词
D O I
10.1373/clinchem.2007.072629
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Gene silencing through aberrant CpG island methylation is the most extensively analyzed epigenetic event in human tumorigenesis and has huge diagnostic and prognostic potential. Methylation patterns are often very heterogeneous, however, presenting a serious challenge for the development of methylation assays for diagnostic purposes. Methods: We used Pyrosequencing (TM) technology to determine the methylation status of 68 CpG sites in the CpG island of the CDKN2B gene [cyclin-dependent kinase inhibitor 213 (p15, inhibits CDK4)], frequently hypermethylated in myeloid malignancies, in a series of bone marrow samples from patients with myelodysplasia and myeloid leukemia (n=82) and from 32 controls. A total of 7762 individual methylation sites were quantitatively evaluated. Precision and reproducibility of the quantification was evaluated with several overlapping primers. Results: The use of optimized sequencing primers and the new Pyro Q-CpG (TM) software enabled precise and reproducible quantification with a single sequencing primer of up to 15 CpG sites distributed over similar to 100 bp. Extensive statistical analyses of the whole CpG island revealed for the first time disease-specific methylation patterns of the CDKN2B gene in myeloid malignancies and small regions of differential methylation with high discriminatory power that enabled differentiation of even low-grade myelodysplastic syndrome samples from the controls, a result that was confirmed in an independent group of 9 control and 36 patient samples. Conclusion: The precise quantitative methylation mapping of whole CpG islands is now possible with Pyrosequencing software in combination with optimized sequencing primers. This method reveals disease-specific methylation patterns and enables the development of specific diagnostic assays. (c) 2007 American Association for Clinical Chemistry
引用
收藏
页码:17 / 23
页数:7
相关论文
共 27 条
[1]  
Aggerholm A, 1999, CANCER RES, V59, P436
[2]   Low level of DAP-kinase DNA methylation in myelodysplastic syndrome [J].
Brakensiek, K ;
Länger, F ;
Kreipe, H ;
Lehmann, U .
BLOOD, 2004, 104 (05) :1586-1587
[3]   Multiplexed profiling of candidate genes for CpG island methylation status using a flexible PCR/LDR/Universal Array assay [J].
Cheng, YW ;
Shawber, C ;
Notterman, D ;
Paty, P ;
Barany, F .
GENOME RESEARCH, 2006, 16 (02) :282-289
[4]   Sensitive and quantitative universal Pyrosequencing™ methylation analysis of CpG sites [J].
Colella, S ;
Shen, L ;
Baggerly, KA ;
Issa, JPJ ;
Krahe, R .
BIOTECHNIQUES, 2003, 35 (01) :146-+
[5]   Molecular diagnostic applications of DNA methylation technology [J].
Cottrell, SE .
CLINICAL BIOCHEMISTRY, 2004, 37 (07) :595-604
[6]   De novo quantitative bisulfite sequencing using the pyrosequencing technology [J].
Dupont, JM ;
Tost, J ;
Jammes, H ;
Gut, NG .
ANALYTICAL BIOCHEMISTRY, 2004, 333 (01) :119-127
[7]   Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry [J].
Ehrich, M ;
Nelson, MR ;
Stanssens, P ;
Zabeau, M ;
Liloglou, T ;
Xinarianos, G ;
Cantor, CR ;
Field, JK ;
van den Boom, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (44) :15785-15790
[8]   Aberrant DNA methylation as a cancer-inducing mechanism [J].
Esteller, M .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 :629-656
[9]   The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 [J].
Harris, NL ;
Jaffe, ES ;
Diebold, J ;
Flandrin, G ;
Muller-Hermelink, HK ;
Vardiman, J ;
Lister, TA ;
Bloomfield, CD .
MODERN PATHOLOGY, 2000, 13 (02) :193-207
[10]   Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate [J].
Issa, JPJ ;
Gharibyan, V ;
Cortes, J ;
Jelinek, J ;
Morris, G ;
Verstovsek, S ;
Talpaz, M ;
Garcia-Manero, G ;
Kantarjian, HM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (17) :3948-3956